A head-to-head comparison of two new type 2 diabetes drugs produced mixed results. In the study, liraglutide (Victoza) was somewhat better than the other drug, exenatide (Bydureon), in lowering blood sugar and weight, but Bydureon was associated with fewer side effects, researchers said. Victoza is injected daily by patients and Bydureon is injected weekly. Both drugs are classified as “glucagon-like peptide-1 receptor agonists.”
